|
Characteristic
|
Number of patients
|
|---|
|
Four consecutive weeks
|
2-week on/1-week off
|
|---|
|
5 mg/person
|
10 mg/person
|
10 mg/person
|
12 mg/person
|
16 mg/person
|
|---|
|
Total
| |
4
|
4
|
3
|
21
|
3
|
|
Sex
|
Male
|
2
|
2
|
2
|
15
|
1
|
|
Female
|
2
|
2
|
1
|
6
|
2
|
|
Age, year
|
Median
|
39
|
50
|
60
|
47
|
45
|
|
Range
|
21–49
|
39–60
|
53–65
|
32–60
|
48–55
|
|
ECOG score
|
0
|
0
|
1
|
0
|
9
|
0
|
|
1
|
4
|
3
|
3
|
12
|
3
|
|
Pretreatment
|
Surgery
|
3
|
4
|
2
|
18
|
2
|
|
Radiotherapy
|
2
|
1
|
3
|
6
|
1
|
|
Chemotherapy
|
4
|
4
|
3
|
15
|
3
|
|
Tumor site
|
Sarcoma
|
2
|
1
|
1
|
4
|
1
|
|
MTC
|
0
|
0
|
0
|
6
|
0
|
|
CC
|
1
|
2
|
0
|
0
|
1
|
|
NSCLC
|
0
|
0
|
1
|
3
|
0
|
|
RC
|
0
|
0
|
0
|
4
|
0
|
|
Other
|
1
|
1
|
1
|
4
|
1
|
-
ECOG Eastern Cooperative Oncology Group, MTC medullary thyroid carcinoma, CC colorectal carcinoma, NSCLC non-small cell lung cancer, RC renal carcinoma
